In a setback for Danish drugmaker Genmab, topline results from a Phase 3 study showed combining the company's drug Arzerra with bendamustine did not improve progression-free survival in indolent non-Hodgkin lymphoma (NHL) compared to bendamustine alone.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,